Clinical trials: Respiratory Symptoms
Pulmonary Disease, Chronic Obstructive
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
Study to obtain further information on the tolerability and efficacy of Ventilat® metered-dose inhaler in the treatment of Chronic Obstructive bronchitis under conditions of daily practice
- Trial name
- NCT02233920
- Testing
- Ventilat® - metered dose inhaler
- Volunteers
- 716 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer, NSCLC
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent…
- Trial name
- NCT04746924
- Testing
- Tislelizumab, Ociperlimab, Pembrolizumab
- Where
- 218 sites in United States, Argentina and 17 more
- Volunteers
- 669 people
- Sponsor
- BeiGene
COVID-19
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for…
- Trial name
- EMPATHY (NCT04828161)
- Testing
- ensovibep
- Where
- 48 sites in United States, Hungary and 3 more
- Volunteers
- 407 people
- Sponsor
- Novartis Pharmaceuticals
Snoring, Obstructive Sleep Apnea
Intraoral Tongue Stimulation for Treatment of Primary Snoring
Intraoral Neuromuscular Training for Treatment of Snoring Objective Studies show that improving pharyngeal muscle tone can ameliorate obstructive sleep apnoea (OSA) and snoring.
- Trial name
- NCT03829956
- Testing
- Intraoral tongue stimulator (Snoozeal)
- Where
- United Kingdom
- Volunteers
- 115 people
- Sponsor
- Signifier Medical Technologies
Chronic Obstructive Pulmonary Disease, Bronchitis
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00250679
- Testing
- Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID
- Where
- 60 sites in United States
- Volunteers
- 443 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study is designed to collect long term safety data of indacaterol (300 µg o.d.) in Japanese patients with moderate to severe COPD. Data from this study will be used for the registration of indacaterol in Japan.
- Trial name
- NCT00876694
- Testing
- Indacaterol 300 µg, Salmeterol 50 µg
- Where
- 37 sites in Japan
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00796653
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 98 sites in Argentina, Brazil and 18 more
- Volunteers
- 937 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
- Trial name
- NCT00683722
- Testing
- Prochymal™
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Mesoblast, Inc.
Pulmonary Disease, Chronic Obstructive
To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)
The study will be conducted in a single-center, randomized, single-blinded, placebo-controlled, dose escalation design with two dose groups.Multiple-dose inhalation of Ciprofloxacin inhale 50 and 75 mg or placebo will be…
- Trial name
- NCT01072942
- Testing
- Ciprofloxacin (Cipro InhaIe, BAYQ3939)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Stress, Psychological, Loneliness
Ecological Momentary Assessment and Text Message Intervention for Stress Management
Feasibility and acceptability of an Ecological Momentary Assessment (EMA) compared with an EMA plus automated text message intervention for stress management
- Conditions
- Stress, Psychological, Loneliness, Covid19, Stress
- Trial name
- NCT04907942
- Testing
- EMA + EMA and FACE Stress, EMA Alone
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Click Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity
The primary objective of this study is to investigate the effect of tiotropium vs. placebo on trough FEV1 and FEV1 2 hours post inhalation after 12 weeks of treatment. For both endpoints changes from baseline will be analysed.
- Trial name
- NCT00274573
- Testing
- Tiotropium bromide
- Where
- 177 sites in Germany
- Volunteers
- 1,639 people
- Sponsor
- Boehringer Ingelheim
Alpha1-Antitrypsin Deficiency
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein.
- Trial name
- NCT05899673
- Testing
- Fazirsiran Injection
- Where
- 10 sites in United States, Austria and 3 more
- Volunteers
- 31 people
- Sponsor
- Takeda
Chronic Obstructive Pulmonary Disease
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered DS102 capsules versus placebo in the treatment of adult patients with Chronic…
- Trial name
- NCT03414541
- Testing
- DS102
- Where
- 3 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Afimmune
Chronic Obstructive Pulmonary Disease
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
A clinical trial to investigate the pharmacokinetics, safety and tolerability of CHF6001 after single administrations in participants with mild, moderate and severe liver impairment with matched healthy adult volunteers
- Trial name
- NCT05373953
- Testing
- CHF6001
- Where
- Bulgaria
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Cheyne-Stokes Respiration, Sleep Apnea, Central
Bipap Automatic Servo Ventilation (autoSV) Advanced in Central Apnea Patients
Pilot study testing the Bipap autoSV Advanced Algorithm during full night, in-lab polysomnography (PSG) and 3 months at home on patients with Central Sleep Apnea, Hunter Cheyne Stokes Respiration, or Complex Sleep Apnea.
- Trial name
- NCT01199042
- Testing
- BiPAP autoSV Advanced
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Philips Respironics
COPD, Dyspnea
Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
Dyspnea is the most common symptom limiting the ability of COPD patients to perform activities of daily living. Although there has been research involving the benefit of providing Non Invasive Ventilation (NIV) during exercise to…
- Trial name
- NCT03349437
- Testing
- Vitabreath Device, Pursed Lip Breathing
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Philips Respironics
Hypoxia
Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia in Neonates
Validate pulse oximeter sensors in neonates by comparing sensor readings to blood samples during cardiac surgery.
- Trial name
- NCT01253772
- Volunteers
- 4 people
- Sponsor
- SterilMed, Inc.
Pulmonary Disease, Chronic Obstructive
TARA Working Prototype Engagement Evaluation: Feasibility Study
TARA is a Digital Behaviour Change Intervention (DBCI) for individuals with Chronic Obstructive Pulmonary Disease (COPD)(IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology.
- Trial name
- NCT04085302
- Testing
- Digital Behaviour Change Intervention
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
COVID-19
Oestrogen Treatment for COVID-19 Symptoms
The aim of this trial is to determine whether oestrogen treatment mitigates disease progression and severity in confirmed COVID19.
- Trial name
- NCT04853069
- Testing
- Transdermal estradiol gel
- Where
- Qatar
- Volunteers
- 2,000 people
- Sponsor
- Hamad Medical Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.